Osteosarcoma: Review of the past, impact on the future. The American experience

Cancer Treatment and Research

Volumn 152, Issue , 2009, Pages 239-262

  Jaffe, Norman ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FOLINIC ACID; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LEXIDRONAM SAMARIUM SM 153; MELPHALAN; MESNA; METHOTREXATE; MITOMYCIN C; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINYLALANYL DIPALMITOYLPHOSPHATIDYLETHANOLAMINE; RAZOXANE; SAMARIUM; TRIMETREXATE; VINCRISTINE; VINCRISTINE SULFATE; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONFERENCE PAPER; DIGESTIVE SYSTEM ULCER; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG WITHDRAWAL; EAR DISEASE; ERYTHEMA; HEART FAILURE; HEMORRHAGIC CYSTITIS; HEPATORENAL SYNDROME; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIMB SALVAGE; LUNG METASTASIS; MALIGNANT FIBROUS HISTIOCYTOMA; MICROMETASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SKIN ULCER; SURVIVAL RATE; TUMOR NECROSIS; TUMOR REGRESSION; UNITED STATES; BONE NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LEUCOVORIN; METHOTREXATE; OSTEOSARCOMA;

EID: 77953669077     PISSN: 09273042     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0284-9_12     Document Type: Conference Paper

References (117)

1. Jaffe N, Traggis D, Enriquez C. Evaluation of a combination of mitomycin C (NSC-26980), phenylalanine mustard (NSC-16210) and vincristine (NSC-6757) in the treatment of osteogenic sarcoma. Cancer Chemother Rep. 1971;55:181-191.
2. Sullivan MP, Sutow WW, Taylor G. l-phenylalanine mustard as treatment for metastatic osteogenic sarcoma in children. J Pediatr. 1963;63:227-237.
3. Sutow WW, Sullivan MP, Fernbach DJ, et al. Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. Cancer. 1975;36:1598-1602.
4. Wilbur JR, Sutow WW, Sullivan MP, et al. Successful treatment of rhabdomyosarcoma with combination chemotherapy and radiation therapy. Proc ASCO. 1971;7:56.
5. Sutow WW, Sullivan MP, Wilbur JR, et al. The study of adjuvant chemotherapy in osteogenic sarcoma. J Clin Pharmacol. 1975;15:530-533.
6. Pinkel D. Cyclophosphamide in children with cancer. Cancer. 1962;15:42-49.
7. Finklestein J, Hittle RE, Hammond CD. Evaluation of a high-dose cyclophosphamide regimen in childhood tumors. Cancer. 1969;23:1239-1242.
8. Sutow WW. Chemotherapeutic management of childhood rhabdomyosarcoma. In: Taylor G, Sutow WW, eds. Neoplasia in Childhood. Chicago: Year Book Medical Publishers; 1969: 201-208.
9. Cortes EP, Holland JF, Wang JJ, et al. Chemotherapy of advanced osteosarcoma. In: Price CHG, Ross FCM, eds. Colston Paper N.24 Bone-Urban Aspects of Neoplasia. London: Buttersworth; 1972:265-280.
10. Sutow WW. Combination chemotherapy with Adriamycin (NSC-123127) in primary treatment of osteogenic sarcoma (Part III). Cancer Chemother Rep. 1975;6:315-317.
11. Sutow WW, Gehan EA, Dyment PC, et al. Multi-drug adjuvant chemotherapy in osteosarcoma. Interim report of the Southwest Oncology Group studies. Cancer Treat Rep. 1978;62: 265-269.
12. Sutow WW. Late metastases in osteosarcoma. Lancet. 1976;1:856.
13. Sutow WW, Herson J, Perez C. Survival after metastasis in osteosarcoma. Natl Cancer Inst Monogram. 1981;56:227-231.
14. Perez C, Herson J, Kimball JC, et al. Prognosis after metastases in osteosarcoma. Cancer Clin Trials. 1978;1:315-320.
15. Jaffe N, Smith E, Abelson HT, Frei E III. Osteogenic sarcoma: Alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol. 1983;1:251-254.
16. Herson J, Sutow WW, Elder K, et al. Adjuvant chemotherapy in non metastatic osteosarcoma A Southwest Oncology Group Study. Med Pediatr Oncol. 1980;8:343-352.
17. Jaffe N, Link M, Traggis D, et al. The role of high-dose methotrexate in osteogenic sarcoma. Sarcomas in soft tissue and bone in childhood. Natl Cancer Inst Monogr. 1981;56:201-206.
18. Goorin AM, Delorey M, Gelber RD, et al. The Dana-Farber Cancer Institute/The Children's Hospital adjuvant chemotherapy trials for osteosarcoma: Three sequential studies. Cancer Treat Symp. 1986;3:155-159.
19. Rosen G, Marcove RC, Huvos AG, et al. Chemotherapy en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer. 1976;37:1-11.
20. Rosen G. Role of chemotherapy in the treatment of primary osteogenic sarcoma. A five-year follow-up of T-10 neoadjuvant chemotherapy. In: Kimura K, Wang Y-M, eds. Methotrexate in Cancer Therapy. New York: Raven Press; 1986:227-238.
21. Delepine N, Delepine G, Jasmine C, et al. Importance of age and methotrexate dosage: Prognosis in children and young adults with high-grade osteosarcoma. Biomed Pharmacother. 1988;42:257-262.
22. Winkler K, Beron G, Dilling G, et al. Neoadjuvant chemotherapy of osteosarcoma. Results of Randomized Cooperative Trial (COSS-82) with salvage. Chemotherapy based on histologic tumor response. J Clin Oncol. 1988;6:329-337.
23. Bacci G, Picci P, Ruggeri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities: The Instituto Rizzoli Experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intra-arterial cisplatin. Cancer. 1990;65:2539-2553.
24. Meyers PA, Heller G, Healey JH, et al. Chemotherapy for non-metastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5-15.
25. Bacci G, Picci P, Avella M, et al. The importance of dose intensity in neoadjuvant chemotherapy of osteosarcoma: A retrospective analysis of high-dose methotrexate, cisplatinum and adriamycin used preoperatively. J Chemother. 1990;2:127-135.
26. Provisor AJ, Ettinger LJ, Nachman JB, et al. Treatment of non-metastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: A report from the Children's Cancer Group. J Clin Oncol. 1997;15:76-84.
27. Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T-12) protocol. J Clin Oncol. 1998;16:2452-2458.
28. Krailo M, Ertel I, Makley J, et al. A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetasatic osteosarcoma: A report from the Children's Cancer Study Group. Med Pediatr. 1987;15:69-77.
29. Bramwell VH, Berger SM, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimen in operative osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol. 1992;10:1579-1591.
30. Souhami RL, Craft AW, Vander Eijken JW, et al. Randomised trial of two in operable regimens of chemotherapy inoperable osteosarcoma: A study of the European Osteosarcoma Intergroup. Lancet. 1997;350:911-917.
31. Grem J, King S, Whittes R, et al. The role of methotrexate in osteosarcoma. J Natl Cancer Inst. 1988;80:626-655.
32. Graf N, Winkler K, Betlemovic M, et al. Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol. 1994;12:1443-1451.
33. Wang Y-N, Sutow WW, Romsdahl MM, et al. Age related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treat Rep. 1979;63:405-410.
34. Jaffe N, Prudich J, Knapp J, et al. Treatment of primary osteosarcoma with intra-arterial and intravenous high-dose methotrexate. J Clin Oncol. 1983;7:428-431.
35. Cohen H, Jaffe N. Pharmacokinetic studies of 24-hour infusions of high-dose methotrexate. Cancer Chemother Pharmacol. 1978;1:61-64.
36. Wang YM, Lantin E, Sutow WW. Blood, urinary and cerebral spinal fluid methotrexate levels in children after high-dose methotrexate infusion. Clin Chem. 1976;22:1053-1056.
37. Wang YN, Kim PY, Lantin E, et al. Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion. Med Pediatr Oncol. 1978;4:221-229.
38. Perez C, Wang Y-M, Sutow WW, et al. Significance of 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials. 1978;1:107-111.
39. Jaffe N, Farber S, Traggis D, et al. Favorable response of metastatic osteogenic sarcoma to past high-dose methotrexate with citrovorin rescue and radiation therapy. Cancer. 1973;31:1367-1373.
40. Rosen G, Tefft M, Martinez A, et al. Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma. Cancer. 1975;35:622-630.
41. Machak GN, Tkachev SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high grade osteosarcoma of the extremities. Mayo Clin Proc. 2003;78:147-155.
42. Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: Experience of the Osteosarcoma Study Group. J Clin Oncol. 2003;21:334-341.
43. Bonnadonna G, Monfardi S, De Lena M, et al. Phase I and preliminary phase II evaluation of Adriamycin (NSC/123127). Cancer Res. 1970;30:2527-2582.
44. Middleman E, Luce L, Frei E. Clinical trials with Adriamycin. Cancer. 1971;28:844-850.
45. O'Bryan RN, Luce JK, Talley R, et al. Phase II evaluation of Adriamycin in human neoplasia. Cancer. 1973;32:1-7.
46. Cortes EP, Holland JF, Wang JJ, et al. Amputation and Adriamycin in primary osteosarcoma. New Engl J Med. 1974;291:998-1000.
47. Cortes EP, Holland JF, Glidewell O. Osteogenic studies by the Cancer and Leukemia Group B. Natl Cancer Inst Monogr. 1975;56:207-209.
48. Cassady JR, Richter NP, Piro AJ, et al. Radiation, Adriamycin interactions - Preliminary clinical observations. Cancer. 1975;36:946-949.
49. Eilber FR, Grant T, Morton C. Adjuvant chemotherapy of osteosarcoma: Preoperative treatment. Cancer Treat Rep. 1978;62:213-216.
50. Jaffe N, Watts H, Fellows KE, et al. Local en bloc resection for limb preservation. Cancer Treat Rep. 1978;62:217-273.
51. Basser Rl, Green MD. Strategies for prevention of anthracycline cardiotoxicity. Cancer Treat Rev. 1994;19:57-77.
52. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin-induced cardiotoxicity. Ann Pharmacother. 1994;28:1063-1072.
53. Smith MA, Ungerleider RS, Horowitz ME, et al. Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst. 1991;83:1460-1470.
54. Baum E, Greenberg L, Gaynon P, et al. Use of Cis- diamminedichloroplatinum-II (CPDD) in Osteogenic Sarcoma (OS) in Children (Abstract C-315). Proc AACR-ASCO. 1978;19:385.
55. Nitschke R, Starling KA, Vats T, et al. Cis-diamminedichloroplatin-II (NSC 119875) In Childhood Malignancies. A Southwest Oncology Group Study. Med Pedatr Oncol. 1978;4: 127-132.
56. Ochs JJ, Freeman AR, Douglass HO Jr, et al. Cis-diamminedichloroplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep. 1978;62:239-245.
57. Jaffe N, Knapp J, Chuang VP, et al. Osteosarcoma intra-arterial treatment of the primary tumor with Cis-diamminedichloroplatinum-II (CDP). Angiographic, pathologic and pharmacologic studies. Cancer. 1983;51:402-407.
58. Jaffe N, Raymond AK, Ayala A, et al. Effect of cumulative courses of intra-arterial Cisdiamminedichloroplatinum II on the primary tumor in osteosarcoma. Cancer. 1989;63:63-67.
59. Wright KC, Wallace S, Kim EE, et al. Pulse arterial infusions. Chemotherapeutic complications. Cancer. 1986;57:1952-1956.
60. Chuang VP, Benjamin RS, Jaffe N, et al. Radiographic and angiographic changes in osteosarcoma after intra-arterial chemotherapy. Am J Radiol. 1982;139:1065-1069.
61. Shirkoda A, Jaffe N, Wallace S, et al. Computed tomography of osteosarcoma following intraarterial chemotherapy. Am J Radiol. 1985;144:95-99.
62. Pan G, Raymond AK, Carrasco CH, et al. Osteosarcoma: MR imaging after preoperative chemotherapy. Radiology. 1990;174:517-526.
63. Meyers PA. Osteosarcoma In Pediatric Bone and Soft Tissue Sarcomas. In: Pappo A, ed. Pediatric Bone and Soft Tissue Sarcomas. Berlin, Heidelberg, New York: Springer; 2005: 219-233.
64. Ruiz L, Gilden J, Jaffe N, et al. Auditory function in pediatric osteosarcoma patients treated with multiple doses of cis- diamminedichloroplatinum-II (CDP). Cancer Res. 1989;49: 742-744.
65. Jaffe N, Keifer R III, Robertson R, et al. Renal toxicity with cumulative doses of cis-diamminedichloroplatinum- II in pediatric patients with osteosarcoma. Cancer. 1987;59:1577-1581.
66. Kawai A, Sugihara S, Kunisada T, et al. Imaging assessment of the response of bone tumors to preoperative chemotherapy. Clin Orthop Relat Res. 1997;Apr(337):216-225.
67. Kunisada T, Ozaki T, Kawai A. Imaging assessment of the responses of osteosarcoma patients to preoperative chemotherapy: Angiography compared with thallium-201 scintigraphy. Cancer. 1999;86(6):949-956.
68. Carrasco CH, Charnsangavej C, Raymond AK, et al. Osteosarcoma: Angiographic assessment of response to preoperative chemotherapy. Radiology. 1989;170:839-842.
69. Lang P, Vahlensieck M, Matthay KK. Monitoring neovascularity as an indicator to response to chemotherapy in osteogenic and Ewing sarcoma using magnetic resonance angiography. Med Pediatr Oncol. 1996;26(5):329-333.
70. Kumpan W, Lechner G, Wittich GR. The angiographic response of osteosarcoma following pre-operative chemotherapy. Skeletal Radiol. 1986;15(2):96-102.
71. Wilkins RM, Cullen JW, Odom L, et al. Superior survival in treatment of primary nonmetastatic pediatric osteosarcoma of the extremity. Ann Surg Oncol. 2003;10:498-507.
72. Jaffe N, Spears R, Eftekhari F, et al. Pathologic fracture in osteosarcoma: Effect of chemotherapy in primary Tumor and survival. Cancer. 1987;59:701-709.
73. Antman KH, Montella D, Rosenbaum C, et al. Phase II Trial of ifosfamide with mesna in previously treated metastatic osteosarcoma. Cancer Treat Rep. 1985;69:499-504.
74. Bowman LG, Mayer WN, Douglass EC, et al. Activation of ifosfamide in metastatic and unresectable osteosarcoma (Abstract). Proc ASCO. 1987;C-214:844.
75. Meyer WH, Pratt CB, Farham D, et al. The activity of Ifosfamide (IFOS) in previously pretreated patients with osteosarcoma (OS): Preliminary results of SJCRHOS-86 Study. Proc ASCO. 1988;7:261.
76. Grana N, Graham-Pole J, Cassano W, et al. Etoposide (VP-16) infusion plus Cyclophosphamide (CY) pulses: An effective combination for refractory cancer. Proc ASCO. 1989;8:300.
77. Saleh R, Graham-Pole J, Cassano W, et al. Response of osteogenic sarcoma to the combination of rtoposide and cyclophosphamide as neoadjuvant chemotherapy. Cancer. 1990;65:861-865.
78. Pratt CB, Luo X, Fay L, et al. Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide. A single hospital experience. Med Pediatr Oncol. 1996;27:145-148.
79. Harris MB, Cantor AB, Goorin AM. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. Med Pediatr Oncol. 2002;20:426-433.
80. Pratt CB, Meyer WH, Dauglass EC, et al. A phase I study of ifosfamide with Mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer. 1993;71: 3661-3665.
81. Chawla S, Rosen G, Lowenbraun S, et al. Role of high-dose ifosfamide in recurrent osteosarcoma. Proc ASCO. 1990;9:310.
82. Patel S, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft tissue sarcomas: Results of a Phase II and Pilot Studies - dose-response and schedule dependence. J Clin Oncol. 1997;15:2378-2384.
83. Berrak S, Pearson P, Berbergoglu S, et al. High-dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity. Pediatr Blood Cancer. 2005;44:215-219.
84. Pratt CB, Meyer WH, Rao BN, et al. Osteosarcoma studies at St Jude Children's Research Hospital from 1968 through 1998. Cancer Treat Res. 1993;62:323-326.
85. Harris MB, Gieser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: A Pediatric Oncology Group Study. J Clin Oncol. 1998;16:3641-3648.
86. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: A Pediatric Oncology Group Trial. J Clin Oncol. 2002;20:426-433.
87. Daw NC, Billups CA, Rodroguez-Galindo C, et al. Metastatic osteosarcoma. Cancer. 2006;106:403-412.
88. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/Ifosfamide window therapy for osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 Trial. J Clin Oncol. 2001;19:171-182.
89. Fergusen WS, Harris MB, Goorin AM, et al. Presurgical window of carboplatin and surgery and multi-drug chemotherapy for the treatment of newly diagnosed metastatic or unresectable osteosarcoma: Pediatric Oncology Group trial. J Pediatr Hematol Oncol. 2001;23:340-348.
90. Petrilli AS, de Camargo B, Filho VO, et al. Results of the osteosarcoma treatment group studies III and IV: Prognostic factors and impact on survival. J Clin Oncol. 2006;24:1161-1168.
91. Merimsky O, Meller I, Flusser G, et al. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A phase II study. Cancer Chemother Pharmacol. 2000;45:177-181.
92. Navid F, Willert JR, Mc Carville MB, et al. Combination of gemcitibine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer. 2008;113:419-425.
93. Anderson PM, Wiseman GA, Dispenzieri A, et al. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: Low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:189-196.
94. Meyers P, Schwartz CL, Krailo M, et al. Osteosarcoma: A randomized prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004-2011.
95. Lu L, Lu L. Junovan fails to win ODAC nod for osteosarcoma treatment. ONI. 2007;16:1632.
96. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633-638.
97. Bielack SS, Marina N, Ferrari S, et al. Osteosarcoma: The same old drugs or more? Journal Clin Oncol. 2008;26:3192-3193.
98. Hunsberger S, Freidlin B, Smith MA. Complexities in interpretation of osteosarcoma clinical trial results. Journal Clin Oncol. 2008;26:3193-3194.
99. Meyers PA, Schwartz CL, Krailo MD, et al. In Reply Journal. Clin Oncol. 2008;26:3194-3195.
100. Gitelis S, Neel MD, Wilkins RM, et al. The use of a closed expandable prosthesis for pediatric sarcomas. Chir Organi Mov. 2003;88:327-333.
101. Hudson M, Jaffe MR, Jaffe N, et al. Pediatric osteosarcoma: Therapeutic strategies, results and prognostic factors derived from a 10-year experience. J Clin Oncol. 1990;8:1988-1997.
102. Hosalkar HS, Dormans JP. Limb sparing surgery for pediatric musculoskeletal tumors. Pediatr Blood Cancer. 2004;42(4):295-310.
103. Jaffe N, Carrasco H, Raymond K, et al. Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? Cancer. 2002;95:2202-2210.
104. Kaste SC, Pratt CB, Cain AM, et al. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: Imaging features. Cancer. 1999;86(8):1602-1608.
105. Meyers PA, Heller G, Healy JH, et al. Osteogenic sarcoma with clinically detectable pulmonary metastases at initial presentation. J Clin Oncol. 1993;11:449-453.
106. Su WT, Chewning J, Abramson S, et al. Surgical management and outcome of osteosarcoma patients with unilateral pulmonary metastases. J Pediatr Surg. 1994;39(3):1849-1858.
107. Meyer WH, Schell MJ, Kumar AP, et al. Thoracotomy for pulmonary metastatic osteosarcoma. An analysis of prognostic indicators of survival. Cancer. 1987;59(2):374-379.
108. Skinner KA, Eilber FR, Holmes E, et al. Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch Surg. 1992;127(90):1065-1070. discussion 1070-1071
109. Chou AJ, Merola P, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: The Memorial Sloan-Kettering Cancer Center experience. Cancer. 2005;104(10):2214-2221.
110. Harting MT, Blakely ML, Jaffe N, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41(1):194-199.
111. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol. 1994;12(9):1849-1858.
112. Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the Istituto Ortopedico Rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol. 2000;18(24):4016-4027.
113. Nathan SS, Gorlick R, Bukata S, et al. Treatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasis. Cancer. 2006;107(7):1607-1616.
114. Bielack SS, Kempf-Bielack B, Branscheid D, et al. Second and subsequent recurrences of osteosarcoma: Presentation and treatment outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group patients. J Clin Oncol. 2008;27:557-565.
115. McCarten KM, Jaffe N, Kirkpatrick JA. The changing radiographic appearance of osteosarcoma. Ann Radiol. 1980;23:203-208.
116. Lockhart SK, Coan JD, Jaffe N, et al. Osteosarcoma metastatic to the kidney. Clin Imaging. 1989;13:154-156.
117. Baram TZ, Van Tassel P, Jaffe N. Brain metastases in osteosarcoma: Incidence, clinical and neurological findings and management options. J Neuro Oncol. 1988;6:45-52.